Kura Oncology to present cancer drug data

Kura Oncology is set to present new data on its darlifarnib drug, in combination with cabozantinib, for patients with clear cell renal cell carcinoma. The presentation will occur at IKCS Europe 2026. These findings build upon previous data and aim to demonstrate the potential of darlifarnib to overcome treatment resistance and improve outcomes for patients who have previously received cabozantinib therapy. This research is crucial for advancing cancer treatment options.